Table 1 Immune checkpoint inhibitors approved by the Food and Drug Administration in USA
| Â | Ipilimumab CTLA-4 | Nivolumab PD-1 | Pembrolizumab PD-1 | Atezolizumab PD-L1 | Avelumab PD-L1 | Durvalumab PD-L1 |
|---|---|---|---|---|---|---|
Malignancy | ||||||
 Melanoma | √*(3/2011) | √*(12/2014) | √*(9/2014) |  |  |  |
 Non-small cell lung cancer |  | √ (3/2015) | √ (10/2015) | √ (10/2016) |  |  |
 Renal cell carcinoma |  | √ (11/2015) |  |  |  |  |
 Hepatocellular carcinoma |  | √ (9/2017) |  |  |  |  |
 Classical Hodgkin’ s lymphoma |  | √ (5/2016) | √ (3/2017) |  |  |  |
 Head & neck squamous cell carcinoma4 |  | √ (11/2017) | √ (8/2016) |  |  |  |
 Urothelial Carcinoma |  | √ (2/2017) | √ (5/2017) | √*(5/2016) | √ (5/2017) | √*(5/2017) |
 Colorectal cancer with high msi/mrd |  | √ (8/2017) |  |  |  |  |
 Gastric cancer |  |  | √ (9/2017) |  |  |  |
 Solid tumor with high msi/mrd |  |  | √ (7/2017) |  |  |  |
 Merkel-cell carcinoma |  |  |  |  | √* (3/2017) |  |
 Bladder Cancer |  |  |  | √ (04/2017) |  |  |